Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BTAI 
BioXcel Therapeutics Inc (BTAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BTAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.41% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.90M USD | Price to earnings Ratio - | 1Y Target Price 36.25 |
Price to earnings Ratio - | 1Y Target Price 36.25 | ||
Volume (30-day avg) 9237001 | Beta 0.64 | 52 Weeks Range 1.29 - 48.72 | Updated Date 04/11/2025 |
52 Weeks Range 1.29 - 48.72 | Updated Date 04/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -23.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2858.2% |
Management Effectiveness
Return on Assets (TTM) -72.3% | Return on Equity (TTM) -1766.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82005901 | Price to Sales(TTM) 4.37 |
Enterprise Value 82005901 | Price to Sales(TTM) 4.37 | ||
Enterprise Value to Revenue 36.19 | Enterprise Value to EBITDA -0.75 | Shares Outstanding 5468040 | Shares Floating 4659457 |
Shares Outstanding 5468040 | Shares Floating 4659457 | ||
Percent Insiders 9.55 | Percent Institutions 8.6 |
Analyst Ratings
Rating 3.5 | Target Price 2.81 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioXcel Therapeutics Inc
Company Overview
History and Background
BioXcel Therapeutics Inc. was founded in 2010. It's a biopharmaceutical company utilizing artificial intelligence approaches to identify improved therapies in neuroscience and immuno-oncology. They focus on drug development and commercialization within these therapeutic areas.
Core Business Areas
- Neuroscience: Development and commercialization of treatments for acute agitation associated with schizophrenia, bipolar disorder I or II, and dementia, including Alzheimer's disease. Focus on BXCL501 (dexmedetomidine) for this indication.
- Immuno-oncology: Exploration of potential therapies to treat cancer, targeting various pathways and immune responses. Currently less focused on this segment.
Leadership and Structure
Vimal Mehta, Ph.D., serves as the Chief Executive Officer. The company has a typical corporate structure with various departments like research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- BXCL501 (Igalmi): A sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Market share is still developing due to recent launch. Competitors include antipsychotics (e.g., haloperidol, lorazepam) and other sedatives used off-label.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant regulatory hurdles. The neuroscience market, specifically for acute agitation, is large and underserved.
Positioning
BioXcel Therapeutics is positioned as an innovator using AI to develop novel therapies. Their focus on acute agitation with a novel delivery method provides a potential competitive advantage.
Total Addressable Market (TAM)
The TAM for acute agitation is estimated to be several billion USD annually. BioXcel is positioned to capture a portion of this market with Igalmi, depending on market penetration and clinical adoption.
Upturn SWOT Analysis
Strengths
- Novel AI-driven drug discovery platform
- FDA-approved product (Igalmi)
- Focus on underserved neuroscience market
- Experienced management team
Weaknesses
- Limited commercialization experience
- Dependence on a single approved product
- High cash burn rate
- Relatively small market capitalization
Opportunities
- Expansion of Igalmi's label to other indications (e.g., dementia)
- Potential partnerships and collaborations
- Development of new AI-discovered therapies
- Growing awareness and acceptance of novel psychiatric treatments
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges and delays
- Reimbursement hurdles for new therapies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- OTLK
Competitive Landscape
BioXcel Therapeutics faces competition from larger pharmaceutical companies with established products in the neuroscience space. Their advantage lies in their innovative AI platform and a novel drug delivery method, but they need to overcome challenges related to commercialization and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily marked by research and development milestones, clinical trial results, and regulatory approvals rather than revenue growth.
Future Projections: Future growth is contingent on the successful commercialization of Igalmi and the development of new therapies. Analyst estimates vary depending on market adoption rates and clinical trial outcomes.
Recent Initiatives: Recent initiatives include the commercial launch of Igalmi, ongoing clinical trials for other indications, and continued investment in AI-driven drug discovery.
Summary
BioXcel Therapeutics is a biopharmaceutical company with a promising AI-driven platform and an FDA-approved product, Igalmi. While its innovative approach is a strength, it faces challenges related to commercialization, competition from larger companies, and a high cash burn rate. Successful expansion of Igalmi's label and development of new therapies are crucial for future growth and long-term sustainability. The company needs to carefully manage its financial resources and demonstrate the clinical and economic value of its products to achieve broader market adoption.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
OTLK
OUTLOOK THERAPEUTICS INC
OTLK
OUTLOOK THERAPEUTICS INC
Sources and Disclaimers
Data Sources:
- BioXcel Therapeutics Inc. website
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary. Consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioXcel Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-03-08 | Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.